Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap®

COPENHAGEN, Denmark, June 26, 2026 — Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company has been added to the broad-market Russell 3000® Index, the large-cap Russell 1000® Index, the small-to-mid-cap Russell 2500® Index, and the Russell Midcap® Index as a part of the 2026 Russell U.S. Indexes semi-annual reconstitution, effective at the close of U.S. equity markets on June 26, 2026.

The Russell 3000® Index tracks the largest 3,000 U.S. stocks, representing approximately 98% of investable U.S. equities by market capitalization. Within the Russell 3000®, the Russell 1000® Index comprises the 1,000 largest securities, representing more than 90% of investable U.S. equities; the Russell 2500® Index comprises the 2,500 smallest securities, spanning the small-to-mid-cap segment; and the Russell Midcap® Index comprises the 800 smallest companies within the Russell 1000®. Inclusion in the Russell 1000®, Russell 2500®, and Russell Midcap® Indexes results in automatic inclusion in the appropriate growth and value style indexes.

Russell U.S. Indexes are widely used by investment managers and institutional investors as the basis for index funds and as benchmarks for active investment strategies. According to market data as of December 31, 2024, approximately $11.8 trillion in assets are benchmarked against Russell U.S. Indexes.

For more information on the Russell Indexes and the semi-annual reconstitution process, please visit the “Russell Reconstitution” section of the FTSE Russell website.

About Ascendis Pharma A/S

Ascendis Pharma is a global biopharmaceutical company focused on applying our innovative TransCon technology platform to make a meaningful difference for patients. Guided by our core values of Patients, Science, and Passion, and following our algorithm for product innovation, we apply TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Europe and the United States. Please visit ascendispharma.com to learn more.

Investor Contact

Media Contact

Chad Fugere

Melinda Baker

Ascendis Pharma

Ascendis Pharma

+1 (650) 519-7494

+1 (650) 709-8875